pac.dog pac.dog / Lobbying

1st Quarter - Report · 2026

Filing UUID
b61e96b2-3412-4795-9479-cc82759463cf
Type
Q1 — 1st Quarter - Report
Period
first_quarter
Year
2026
Posted
2026-04-16 19:47:11
Income (reported)
Expenses (reported)
$130,000
Expenses method
A
Filing document
Open on lda.senate.gov

Registrant (lobbying firm)

LUNDBECK LLC

Specialty and Central Nervous System Bio-pharmaceutical manufacturing

Contact
HEATHER STRAWN
Phone
+1 202-412-1563
Address
zip:20004, city:Washington, state:DC, street:1455 Pennsylvania Ave NW Suite 400

Client

LUNDBECK LLC

State
DC
Country
US
Government-entity client
false
Effective date
2009-03-01

Issues lobbied + lobbyists

HCR — Health Issues

Issues pertaining to the 340B Drug Discount Program - H.R. 5256, the 340B ACCESS Act; H.R.4581 & S. 2372, 340B PATIENTS Act of 2025 Issues pertaining to Pharmacy Benefit Managers - H.R.4317, PBM Reform Act of 2025; H.R.6703, Lower Health Care Premiums for All Americans Act Step therapy reform - H.R. 5509 & S. 2903, Safe Step Act Neuroscience Drug Program - FY 2026 and FY2027 AgFDA Appropriations BRAIN Initiative - FY 2026 and FY2027 Labor-HHS Appropriations Reauthorization of the Pediatric Priority Review Voucher program at the FDA Issues related to DTC advertising regulations Pediatric rare diseases - H.R. 1262 & S. 932, Give Kids a Chance Act of 2025 Headache disorders treatment and research - H.R. 5536, HEADACHE Act of 2025 Research and services for epilepsy - H.R. 1189 & S. 494, National Plan for Epilepsy Act

Lobbyists: HEATHER STRAWN; HAYLEY ALEXANDER [new]; ZACHARY POSS [new]; DARBIN WOFFORD [new]

Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE

MMM — Medicare/Medicaid

Issues pertaining to the 340B Drug Discount Program - H.R. 5256, 340B ACCESS Act; H.R.4581 & S. 2372, 340B PATIENTS Act of 2025 Issues pertaining to the implementation of the Inflation Reduction Act of 2022 - H.R. 6166, Lowering Drug Costs for American Families Act Issues pertaining to Pharmacy Benefit Managers - S.3345, PBM Price Transparency and Accountability Act; H.R.4317, PBM Reform Act of 2025 Issues pertaining to CMS Coverage of APS in LTC Issues pertaining to Medicares Six Protected Classes policy Medicare Part D Smoothing Benefit - FY 2026 and FY2027 Labor-HHS Appropriations Orphan drug exclusion in the Inflation Reduction Act - H.R. 946 & S. 1862, ORPHAN Cures Act Small molecule discrepancy in the Inflation Reduction Act - H.R. 1492 & S. 832, The EPIC Act Issues pertaining to the Most Favored Nation drug price setting policy - H.R. 7837, Most Favored Patient Act of 2026 Issues pertaining to migraine screening for women in Medicare - FY 2026 and FY2027 Labor-HHS Appropriations

Lobbyists: HEATHER STRAWN; HAYLEY ALEXANDER [new]; ZACHARY POSS [new]; DARBIN WOFFORD [new]

Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE

TRD — Trade (domestic/foreign)

Tariffs on pharmaceutical products

Lobbyists: HAYLEY ALEXANDER; HEATHER STRAWN; ZACHARY POSS [new]; DARBIN WOFFORD [new]

Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE

pac.dog is a free, independent, non-partisan research tool. Every candidate, committee, bill, vote, member, and nonprofit on this site is mirrored from primary U.S. government sources (FEC, congress.gov, govinfo.gov, IRS) and each state's Secretary of State / election commission — no third-party data vendors, no paywall, no editorial intermediation. Citations to the originating source are on every detail page.

Estimated value: $180/mo per user — but we made it free.